Ustekinumab (Stelara, Yesintek)





PATIENT INFO	RMATION	Referral Statu	s: □ New Re	eferral 🗆 Up	odated Orde	r	
Patient Name:			DOB:	F	Patient Phon	ie:	
Patient Address: Patient En					 nail:		
Allergies:			□ NKDA	Weight (lbs/k	g):	Height (in/cm):	
Sex: □ M / □ F	Date of Last Infusion:	Next Due Da	nte:	Preferred L		- 6 - (/ - /	
·							
	ease provide ICD-10 code in spac	-					
Crohn's Disease:							
Plaque Psoriasis:		Psoriatic Arthritis:					
REQUIRED INFORMATION (Choose one) □ Patient will self-administer subcutaneous medication (Referring provider will coordinate with specialty pharmacy) □ Patient would like in-office injection medication (NOTE: some			LABORATORY ORDERS □ Other: IV DOSE PRE-MEDICATION ORDERS				
insurance providers may require attestation from provider stating patient cannot self-administer with reason why such as needle phobia or low dexterity.)			☐ Tylenol ☐ 500mg / ☐ 650mg PO☐ Loratadine 10mg PO☐ Pepcid 20mg ☐ PO / ☐ IVP				
THERAPY ADMINISTRATION & DOSING (Choose one) ☐ Infuse Ustekinumab (Stelara) OR Ustekinumab biosimilar as required by patient's insurance.			☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP ☐ Solumedrol ☐ 40mg / ☐ 125mg IVP ☐ Other: NURSING				
Administer this Ustekinumab product:			☑ Hold infusion and notify provider for:				
For Crohn's/Ulcerative Colitis: ☐ Induction: Administer Ustekinumab mixed in 250ml 0.9% NS over 1 hour on week 0, one time dose only: ☐ 260mg IV x1 dose (weight of up to 55kg) ☐ 390mg IV x1 dose (weight of 55kg to 85kg) ☐ 520mg IV x1 dose (weight greater than 85kg) ☐ Maintenance: Administer Ustekinumab 90mg subcutaneously		g) Skg)	 Signs/symptoms of illness/active infection or cough, night sweats, unexplained weight loss Planned/recent surgical procedures, recent live vaccinations, or neurological changes ✓ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation 				
every 8 weeks			ADDITIONAL ORDERS				
☐ Induction: Adm and week 4: ☐ 45mg ☐ 90mg ☐ Maintenance: A	nsis/Psoriatic Arthritis: inister Ustekinumab subcutaneous subcutaneously (weight less than 1 subcutaneously (weight greater the dminister Ustekinumab 45mg subc	00kg) an 100kg)					
☐ Maintenance: A	reight less than 100kg) Administer Ustekinumab 90mg subc reight greater than 100kg)	utaneously					
PROVIDER INF	ORMATION						
	Preferred Contact Name:			Preferred Contact Email:			
Ordering Provider				vider NPI:			
Referring Practice			Phone:		Fax:		
Practice Address:		(City:	State:		Zip Code:	
Required Document treatment failure	entation: Patient demos, copy of s or contraindications, Colonosco B, Hep B ESR, CRP, for RA: RF, CCP	front and back of py, reason patien	primary and so	econdary insur	ance, 2 mos	st recent OVN including	
Provider Name	(print) P	Provider Signature			Date		

 $Order \ valid \ for \ one \ year \ unless \ otherwise \ indicated. \ IV \ solutions/diluents \ may \ be \ substituted \ as \ allowed \ per \ manufacturer's \ instructions \ as \ necessitated \ by \ product \ availability.$